GHK-Cu, BPC-157 and TB-500 blend (70 mg)
This three-peptide vial is the four-peptide 80 mg blend without KPV: the same 50 mg of GHK-Cu, with 10 mg each of BPC-157 and TB-500. Dropping one ingredient makes it simpler, but it does not make it studied, and it makes GHK-Cu an even larger share of every draw. Sellers often call it 'GLOW'; the name is a market nickname, not an ingredient list, and the same name can mean different contents.
As sold, one vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg. Statuses as of October 3, 2026. Reviewed by the Grey Peptides Editorial Board. Nothing here is a recommendation or a dose, and no seller is named or linked.
Each component at a glance
From our encyclopedia and FDA's July 2026 Pharmacy Compounding Advisory Committee record. Evidence grades follow the rubric on our methodology page.
| Component | Evidence | FDA status | PCAC, July 2026 | WADA 2026 | WADA 2027 | Interactions |
|---|---|---|---|---|---|---|
| GHK-Cu | Low | Research Chemical | Not voted on | Prohibited under S0 (not named) | Prohibited under S0 (not named) | Not yet reviewed |
| BPC-157 | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited (S0) | Prohibited (S0) | Partly reviewed |
| TB-500 | Low | Research Chemical | Recommended (8-6, July 23, 2026); FDA has not acted | Prohibited (S2.3) | Prohibited (S2.3) | Partly reviewed |
What one vial contains: the ratio arithmetic
The vial holds 70 mg in total. Whatever volume of water is added and however much is drawn, every draw carries the components in the same proportions. The table expresses each as a share of the vial, as a multiple of the smallest component (BPC-157), and as a concentration if the whole vial were dissolved in 2 mL or 3 mL of water. These are arithmetic illustrations of what is in the vial, not suggested volumes or doses.
| Component | In the vial | Share | × BPC-157 | In 2 mL | In 3 mL |
|---|---|---|---|---|---|
| GHK-Cu | 50 mg | 71.4% | 5 | 25 mg/mL | 16.67 mg/mL |
| BPC-157 | 10 mg | 14.3% | 1 | 5 mg/mL | 3.33 mg/mL |
| TB-500 | 10 mg | 14.3% | 1 | 5 mg/mL | 3.33 mg/mL |
The Blend & Stack Calculator runs the same arithmetic for any volume and draw, with this composition as a preset (GHK-Cu, BPC-157 and TB-500, 70 mg (50/10/10)).
What is in the vial, as sold
The listings reviewed for our Name Decoder agreed on this composition: 50 mg of GHK-Cu and 10 mg each of BPC-157 and TB-500, 70 mg in all. That consistency is about labels, not contents. Nothing in law or practice ties an unregulated vial to its label, and a certificate of analysis has to name and quantify all three peptides, with purity for each, to tell you anything about the mix.
Without KPV, GHK-Cu rises from 62.5% of the four-peptide vial to 71.4% of this one. Put another way, more than two thirds of what is in the vial is a peptide whose human evidence comes from creams applied to skin.
Why these three?
The marketing logic is that BPC-157 and TB-500 are promoted for tissue repair and GHK-Cu for skin and collagen, so the three together are sold as a recovery or skin-and-repair mix. That is a rationale, not evidence. Each claim rests on that ingredient's own studies, mostly in animals, and no study has asked whether combining them adds anything, takes anything away, or changes their safety. The table above shows how thin the base is: all three are graded low on our evidence scale, and none is approved for any use.
The evidence, ingredient by ingredient
For BPC-157, the human evidence consists of a two-person intravenous safety pilot, in which the infusions were tolerated and the tested markers did not change1, and a single-clinic chart review of knee injections with no control group, in which patients were asked about pain by phone2. Everything else is animal or laboratory work.
For TB-500, there is no human study of the fragment that is sold. The closest evidence is for thymosin beta-4, the natural protein it is modelled on: a randomised safety study of intravenous doses in healthy volunteers3 and a multicentre trial of a topical formulation for venous leg ulcers4. A safety study and a wound gel are a long way from an injected synthetic fragment.
For GHK-Cu, the human studies are topical. After carbon dioxide laser resurfacing, a small trial found patients rated their skin better with a copper peptide cream, while the investigators' measures showed no difference between groups5. Nobody has published a human study of injected GHK-Cu, the form found in blends.
The only combination data: two of the three
BPC-157 with TB-500 is the one pairing in this vial that anyone has given together, and only twice. In a 2026 rat study of repaired Achilles tendons, TB-500 alone produced a significant gain in the force the tendon could bear, the BPC-157-plus-TB-500 group scored better on one tissue-structure scale, and BPC-157 alone did not reach significance overall6. Doses were set per kilogram of body weight, not drawn from a blended vial. In the knee chart review, four patients had received separate injections of BPC-157 and thymosin beta-4, and three reported relief; with no control group and four people, that shows only that the combination has been used2.
Neither report involved GHK-Cu. So the combination this vial is sold as, all three together at 50 to 10 to 10, has no data in people or animals, and we found no published information on whether the three remain stable when dissolved together.
How it compares with the other repair blends
Three common vials share the same core. The two-peptide 20 mg vial contains only BPC-157 and TB-500, 10 mg each. This 70 mg vial adds 50 mg of GHK-Cu. The 80 mg vial adds 10 mg of KPV on top. Each addition brings one more ingredient with its own uncertain evidence, and each makes the blend harder to interpret if anything goes wrong. In this vial, drawing enough to deliver a given amount of BPC-157 always delivers the same amount of TB-500 and five times as much GHK-Cu; the arithmetic table above sets it out. The four-peptide blend page covers KPV, and our comparison of the three nickname blends sets the compositions side by side.
Regulatory status in the United States
None of the three is FDA-approved. BPC-157 and TB-500 were among the six peptides FDA's Pharmacy Compounding Advisory Committee recommended for the compounding list in July 2026, each by 8 votes to 6 with one abstention, against FDA staff's advice7. As of October 3, 2026, FDA had not acted, so neither can be lawfully compounded yet. GHK-Cu for injection cannot be compounded either: its nomination was withdrawn in April 2026, although FDA returned non-injectable GHK-Cu to Category 1 in May and plans to take GHK-Cu to the committee before the end of February 20278. None of this would authorise a pre-mixed three-peptide vial sold online; compounding covers individual substances for individual patients.
For tested athletes
All three ingredients are prohibited at all times. BPC-157 is named under S0, non-approved substances, and TB-500 under S2, peptide hormones, growth factors and related substances9. GHK-Cu is not named, but as a substance with no current approval for human therapeutic use it falls under the S0 catch-all9. Strict liability applies: an athlete is responsible for any prohibited substance found in their sample, whatever the label said.
What to check
Ask for the milligrams of each of the three and a certificate of analysis that quantifies all three by name, from an identified laboratory, for the batch in hand; the COA Decoder shows what a real report contains. And ask whether a fixed mix of three thinly studied ingredients, dominated by one whose evidence is topical, does anything that separate, clearly labelled products could not, with a clinician who knows what is being considered.
Sources
- Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31. PubMed 40131143 ↗
- Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27. PubMed 34324435 ↗
- Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194. PubMed 20536472 ↗
- Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112. PubMed 17495250 ↗
- Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8. PubMed 16847171 ↗
- Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37. PubMed 42542926 ↗
- U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: votes on BPC-157 and TB-500 (8 yes, 6 no, 1 abstain). Page current as of August 6, 2026; re-read October 3, 2026. Source ↗
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories (GHK-Cu, injectable nomination withdrawn; non-injectable in Category 1). Updated May 14, 2026; re-read September 26, 2026. Source ↗
- World Anti-Doping Agency. The 2026 Prohibited List (S0 non-approved substances; S2 peptide hormones, growth factors and related substances), in force January 1 to December 31, 2026; the 2027 List keeps the same statuses for these three. Read in full July 16, 2026. Source ↗
Related: the blends and stacks hub, the Name Decoder, the COA Decoder and the Interaction Matrix. Last updated October 3, 2026.